Matches in Wikidata for { <http://www.wikidata.org/entity/Q80364332> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q80364332 description "clinical trial" @default.
- Q80364332 description "ensayu clínicu" @default.
- Q80364332 description "klinisch onderzoek" @default.
- Q80364332 description "клінічне випробування" @default.
- Q80364332 name "Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)" @default.
- Q80364332 name "Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)" @default.
- Q80364332 type Item @default.
- Q80364332 label "Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)" @default.
- Q80364332 label "Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)" @default.
- Q80364332 prefLabel "Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)" @default.
- Q80364332 prefLabel "Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)" @default.
- Q80364332 P1132 Q80364332-D92DD358-2D23-4C9D-851E-B8E983D588E1 @default.
- Q80364332 P1476 Q80364332-F395369E-5DB3-4B84-ADFD-13725440F572 @default.
- Q80364332 P2899 Q80364332-A5073EED-BAA7-44C1-A786-F0A4D5DCA027 @default.
- Q80364332 P3098 Q80364332-CFAE4E63-F3ED-4C4E-AE3B-3AD1A76BC4E5 @default.
- Q80364332 P31 Q80364332-9AB0D106-1328-4B3B-9E93-540A60E0DE03 @default.
- Q80364332 P4135 Q80364332-62A3EBBA-99AA-4624-89A4-2FD256AA22D0 @default.
- Q80364332 P4844 Q80364332-57C7DE29-8A36-4B6E-A301-9C03925F8AD8 @default.
- Q80364332 P4844 Q80364332-7FFA1F4C-65E8-42BE-AE64-4501894B1BE4 @default.
- Q80364332 P4844 Q80364332-AA085A5D-D2F6-4AC0-9BEA-171A3F1851BC @default.
- Q80364332 P580 Q80364332-AD85DF57-A9D9-407D-AA84-E1FE61479E16 @default.
- Q80364332 P582 Q80364332-8EDA3C7F-014C-450A-92E5-C13FAFB4FE07 @default.
- Q80364332 P6099 Q80364332-53C5FC38-38C7-4149-A135-2BCC4910510E @default.
- Q80364332 P8363 Q80364332-96D1BCF5-C6D9-455B-8DF7-65FB16400F68 @default.
- Q80364332 P1132 "+762" @default.
- Q80364332 P1476 "A Randomized, Open-Label, Controlled, Multicenter Phase III Study of Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone Versus Platinum-based Chemotherapy for First-line Treatment in Subjects With PD-L1 Positive Relapsed or Advanced NSCLC" @default.
- Q80364332 P2899 "+18" @default.
- Q80364332 P3098 "NCT04203485" @default.
- Q80364332 P31 Q30612 @default.
- Q80364332 P4135 "+70" @default.
- Q80364332 P4844 Q415220 @default.
- Q80364332 P4844 Q415588 @default.
- Q80364332 P4844 Q423762 @default.
- Q80364332 P580 "2020-02-15T00:00:00Z" @default.
- Q80364332 P582 "2022-03-31T00:00:00Z" @default.
- Q80364332 P6099 Q42824827 @default.
- Q80364332 P8363 Q78089383 @default.